IBXAI
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Imagion Biosystems Limited - Option Expiring 21-Nov-2021 Deferred
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in IBXAI
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in IBXAI
N/A
IBXAI investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in IBXAI also invest in...
Want more shares? Try these...
Imagion Biosystems Ltd. engages in the research and development of non-radioactive and safe diagnostic imaging technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-06-22. The Company’s principal activity consists of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using superparamagnetic relaxometry. The firm operates through Research and Development segment. Its MagSense technology is a functional imaging agent for detecting cancers and other critical diseases. MagSense technology uses bio-safe magnetic nanoparticles that are cancer-specific. MagSense nanoparticles are specially formulated as an injectable solution for each type of cancer. MagSense applications include breast cancer, prostate cancer, and ovarian cancer. The firm is conducting a Phase I clinical study of its MagSense HER2 imaging agent. Its PrecisionMRX nanoparticles have been developed for magnetic relaxometry and other demanding biomedical applications. Its PrecisionMRX products include Dextran-Coated, mPEG Coated, Oleic Acid Coated and Carboxylic Acid Functionalized.
📊 Share price